慢性丙型肝炎诱发甲状腺疾病危险因素分析

doi:10.3969/j.issn.1672-5069.2015.06.027

Abstract

Zhu Guobing， Wu Linling， Tian Tian， et al.. Risk factors of thyroid?diseases in patients with chronic hepatitis C and hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 669-671.

[1] 戚中田. 丙型肝炎的致病机制及药物治疗.传染病信息,2010,23（4）：196-205.
[2] 潘蕾,魏欣,谢玉梅,等. 聚乙二醇干扰素α-2a 治疗慢性丙型肝炎病毒/乙型肝炎病毒共感染临床疗效.临床肝胆病杂志,2011,27（1）：84-95.
[3] 杨榕,单忠艳,李玉妹,等. 甲状腺自身免疫性抗体与丙型肝炎病毒感染的相关性分析. 中华传染病杂志,2009,27（3）：138-141.
[4] 霍娜,王力芬,范晓红,等. 慢性丙型肝炎患者甲状腺功能异常情况观察. 传染病信息,2011,24（2）：97-98.
[5] Jamil KM,Leedman PJ,Kontorinis N,et al. Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol, 2009,24（6）：1017-1023.
[6] 谢蓉,林丹. 干扰素联合利巴韦林治疗丙型肝炎引发双相甲状腺炎及贫血一例. 海南医学,2013,13（1）：2007-2008.
[7] 黄雁翔,陈新月,马丽娜. 慢性丙型肝炎抗病毒治疗患者甲状腺功能异常及其影响因素. 中华肝脏病杂志,2012,20（3）:216-219.
[8] 武敬,彭雁忠. 慢性丙型肝炎患者血清甲状腺激素水平及甲状腺自身抗体的分析. 临床和实验医学杂志,2010,9（14）：1043-1044.
[9] Pavan MH,Pavin EJ,Gon ales FL Jr,et al. Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C. Braz J Infect Dis,2011,15（5）：449-456.
[10] 亓传旺,陈倩,张会,等. 丙型肝炎病毒感染及抗病毒治疗对甲状腺的影响. 临床肝胆病杂志,2013,29（2）：153-155.
[11] Yang R,Shan Z,Li Y,et al. Prevalence of thyroid autoantibodies in hepatitis C and hepatitis B infection in China. Intern Med,2011,50（8）:811-815.
[12] 马会乐,郭章林,邱国华,等. 聚乙二醇化干扰素-α 2a 治疗慢性丙型肝炎并发甲状腺疾病患者的临床疗效观察. 中国肝脏病杂志（电子版）,2013,5（2）:39-42.
[13] 李艳歌,孙良阁. 干扰素治疗慢性肝炎引起的甲状腺疾病35 例分析. 河南医学研究,2013,11（1）:35-37.
[14] 桂红莲,吴彦文,周惠娟,等. 干扰素治疗慢性病毒性肝炎发生甲状腺功能异常的临床特征和危险因素. 中华传染病杂志,2013,31（2）:87-92.
[15] 邵翠萍,霍娜,范晓红,等. CXCL10 血清水平及单核苷酸多态性与慢性丙型肝炎患者发生甲状腺功能异常的相关性研究. 传染病信息,2013（6）:348-350.

Risk factors of thyroid?diseases in patients with chronic hepatitis C and hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[9]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[10]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[14]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[15]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.